Technical Analysis for TPTX - Turning Point Therapeutics, Inc.

Grade Last Price % Change Price Change
F 74.13 -4.03% -3.11
TPTX closed up 1.77 percent on Thursday, April 15, 2021, on 74 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical TPTX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion -4.03%
Oversold Stochastic Weakness -4.03%
Slingshot Bearish Bearish Swing Setup -2.33%
Wide Bands Range Expansion -2.33%
Oversold Stochastic Weakness -2.33%
Doji - Bullish? Reversal -0.91%
Wide Bands Range Expansion -0.91%
Down 3 Days in a Row Weakness -0.91%
Oversold Stochastic Weakness -0.91%
Wide Bands Range Expansion -1.08%
Older End-of-Day Signals for TPTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% 44 minutes ago
Down 2 % 44 minutes ago
Down 1% 44 minutes ago
Up 1% 44 minutes ago
Fell Below Previous Day's Low 44 minutes ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Turning Point Therapeutics, Inc. Description

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Treatment Of Cancer Oncology Chemical Compounds Small Cell Lung Cancer Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Targeted Therapy Cancer Therapies Advanced Solid Tumors Signal Transduction Turning Protein Kinase Inhibitors Pyrrolidines Kinase

Is TPTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 141.23
52 Week Low 46.86
Average Volume 365,482
200-Day Moving Average 97.98
50-Day Moving Average 107.48
20-Day Moving Average 88.50
10-Day Moving Average 80.75
Average True Range 5.45
ADX 44.83
+DI 12.27
-DI 30.46
Chandelier Exit (Long, 3 ATRs ) 95.28
Chandelier Exit (Short, 3 ATRs ) 89.38
Upper Bollinger Band 107.57
Lower Bollinger Band 69.44
Percent B (%b) 0.2
BandWidth 43.09
MACD Line -9.10
MACD Signal Line -8.59
MACD Histogram -0.5101
Fundamentals Value
Market Cap 3.72 Billion
Num Shares 48.2 Million
EPS -5.25
Price-to-Earnings (P/E) Ratio -14.71
Price-to-Sales 176.00
Price-to-Book 7.91
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.63
Resistance 3 (R3) 81.78 80.47 80.90
Resistance 2 (R2) 80.47 79.35 80.39 80.66
Resistance 1 (R1) 78.85 78.66 79.66 78.70 80.41
Pivot Point 77.54 77.54 77.94 77.47 77.54
Support 1 (S1) 75.93 76.42 76.73 75.78 74.07
Support 2 (S2) 74.61 75.73 74.54 73.82
Support 3 (S3) 73.00 74.61 73.58
Support 4 (S4) 72.85